Camber Capital Management LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Camber Capital Management LP
CRD #298070
SEC #801-113825
CIK #0001444043
AUM
Employees 8 (38% Investors, 0% Brokers)
Fees
Minimum
Phone617-717-6600
Address101 Huntington Avenue
Boston, MA 02199
Source [IAPD] [EDGAR] [Website]
Total AUM ($B)
4.03.22.41.60.80.02011201620212026
Fees and Compensation — Form ADV Part 2A (4/9/2025) [Brochure]
Item 5: Fees and Compensation

A. Description

Camber bases its fees and performance compensation upon a percentage of assets under management
and upon performance. Clients typically pay Camber quarterly management fees no greater than 1.5%
per annum of the balance in such Client’s account or the net asset value of each investor’s investment in
a Client organized as a pooled investment vehicle. Clients also pay to Camber a performance fee equal to
no greater than twenty percent (20%) of the increase in net asset value of a Client’s account or of the
increase in the net asset value of an investor’s investment in a Client organized as a pooled investment
vehicle (after calculation and accrual of management fees) generally determined as of the last business
day of each fiscal year, subject to a high water mark. Such fees and compensation are currently not
negotiable.

B. Fee Billing

Management fees are deducted quarterly from each investor’s ' assets in advance. Any performance fee
is paid annually in arrears (or at the time of withdrawal if such withdrawal occurs prior to the end of a
fiscal year) from Clients' assets.

C. Other Fees and Expenses

Each Client managed by Camber pays or reimburses Camber, as the case may be, for all costs and expenses
related to its investments and its operations, including, without limitation, brokerage and other
transaction costs, clearing and settlement charges, interest and commitment fees on debit balances or
borrowings, borrowing charges on securities sold short, costs of any liability insurance obtained on behalf
of such Client, custody fees, costs of any litigation or investigation involving Client activities,
indemnification expenses, the management fees, the performance fee, consulting expenses, the fees and
expenses of professionals providing services to such Client, including legal, audit, accounting, tax and
administration services for Camber’s pooled investment vehicles as well as director services for Camber's
non-U.S. pooled investment vehicles that are organized as limited companies, any issue or transfer taxes
chargeable in connection with any securities transactions, any entity level taxes, regulatory costs, filing
and license fees, the costs of reporting and providing information and any extraordinary expenses.
Camber or one of its affiliates may elect from time to time to pay certain of a Client’s expenses in addition
to the organizational expenses, including, but not limited to, other operating expenses. Please refer to
Item 12 for more information about brokerage.

D. Fees in Advance

Clients pay management fees quarterly and in advance. Management fees are calculated based on the
balance in each Client's account or net asset value of an investor’s investment in a Client organized as a
pooled investment vehicle as of the beginning of each calendar quarter.

E. Securities Compensation

        Not applicable.

Camber Capital Management LP                                                                               5
Account Minimums and Types of Clients — Form ADV Part 2A (4/9/2025) [Brochure]
Item 7: Types of Clients

Description

Camber currently provides investment advisory services and portfolio management on a discretionary
basis for pooled investment vehicles.

Account Minimums

The Clients that Camber advises have minimum initial investments of $1,000,000, although when Camber
is accepting new managed accounts or investors in a Client, Camber may accept lesser amounts in its sole
discretion.
CIK Period
0001444043
Sector Form 13F Holdings Value ($B)
Zimmer Holdings Inc 0.1
Baxter International Inc 0.1
Humana Inc 0.1
CVS Caremark Corp 0.1
Globus Medical Inc 0.0
Icon PLC /Adr/ 0.0
Ascendis Pharma A/S 0.0
Merck & Co Inc 0.0
GlaxoSmithKline PLC 0.0
Pfizer Inc 0.0
BioMarin Pharmaceutical Inc 0.0
UnitedHealth Group Inc 0.0
Upjohn Inc 0.0
Brookdale Senior Living Inc 0.0
Myriad Genetics Inc 0.0
Evolent Health Inc 0.0
Concentra Group Holdings Parent Inc 0.0
Inogen Inc 0.0
Denali Therapeutics Inc 0.0
Theravance Biopharma Inc 0.0
Anaptysbio Inc 0.0
Orasure Technologies Inc 0.0
 
 
 
 
 
 
 
 
 
Prev | Page 1 | Next
Type Form D Funds Date Sold AUM
HF Camber Capital Fund II LP [2012-02-14] 9.5 M 23.1 M
Offered $9,472,572 · Filed 2022-06-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $1,000,000 · Duration One year or less · Net Assets Decline to Disclose
HF Camber Capital Master Fund LP [2012-02-14] 1,205.9 M 3,681.5 M
Filed 2025-06-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 3 3.7
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 3 3.7
By Discretionary
Discretionary 3 3.7
Non-Discretionary 0 0.0
Total 3 3.7
By Non-United States Persons
Non-United States Persons 1.4
United States Persons 2.3
Total 3 3.7
Form D Directors Role # Filings # Firms 2011 - 2026
Stephen Dubois Executive Officer 4 2
Camber Capital Management LLC Promoter 4 2
Camber Capital Partners LLC Executive Officer, Promoter 3 2
Camber Capital Management LP Promoter 3 2
Camber Capital Partners II LLC Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001444043]
3 [0001444043]
4 [0001444043]
SC 13D [0001444043]
SC 13G [0001444043]
Form 13D/13G Filer Form 13D/13G Subject Filed
Camber Capital Management LP PTC Therapeutics Inc [2023-10-30]
Camber Capital Management LP Inogen Inc [2023-07-24]
Camber Capital Management LP Orasure Technologies Inc [2023-02-02]
Camber Capital Management LP Solid Biosciences Inc [2022-12-12]
Camber Capital Management LP Quanterix Corp [2022-08-19]
Camber Capital Management LP Myriad Genetics Inc [2022-05-12]
Camber Capital Management LP Zimvie Inc [2022-03-21]
Camber Capital Management LP Orasure Technologies Inc [2021-11-08]
Camber Capital Management LP Orasure Technologies Inc [2021-07-29]
Camber Capital Management LP AVROBIO Inc [2020-11-30]
View All
Firm Profile (Form ADV)
Discretionary AUM$3.3B
ServesInstitutional
Fund TypesHedge Fund
LEI549300DBP8IT426I0Z73
Form 3/4/5 Subject 2011 - 2026
Camber Capital Management LP
ZimVie Inc
AMAG Pharmaceuticals Inc
Endologix Inc /DE/
Protalix BioTherapeutics Inc
Cardiovascular Systems Inc
Sequenom Inc
World Heart Corp
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
ZimVie Inc ZIMV
Common Stock
2024-08-02 Sell 525,000 $17.71 9,297,750
AMAG Pharmaceuticals Inc AMAG
Common Stock
2020-10-01 Sell 4,390,000 $13.57 59,572,300
AMAG Pharmaceuticals Inc AMAG
Common Stock
2019-08-09 Buy 26,600 $8.94 237,804
AMAG Pharmaceuticals Inc AMAG
Common Stock
2019-08-09 Buy 3,400 $9.18 31,212
AMAG Pharmaceuticals Inc AMAG
Common Stock
2019-08-07 Buy 4,000 $7.58 30,320
AMAG Pharmaceuticals Inc AMAG
Common Stock
2019-08-07 Buy 301,000 $7.79 2,344,790
AMAG Pharmaceuticals Inc AMAG
Common Stock
2019-08-07 Buy 50,000 $7.74 387,000
Protalix BioTherapeutics Inc PLX
Common Stock
2016-12-02 Sell 2,500,000 $0.32 800,000
Cardiovascular Systems Inc CSII
Common Stock
2016-09-20 Sell 57,000 $23.54 1,341,780
Cardiovascular Systems Inc CSII
Common Stock
2016-09-19 Sell 1,043,000 $23.25 24,249,750
Cardiovascular Systems Inc CSII
Common Stock
2016-02-23 Buy 250,000 $7.55 1,887,500
Sequenom Inc SQNM
Common Stock
2016-01-04 Buy 75,000 $1.59 119,250
Sequenom Inc SQNM
Common Stock
2015-12-31 Buy 395,435 $1.64 648,513
Sequenom Inc SQNM
Common Stock
2015-12-30 Buy 195,000 $1.59 310,050
Sequenom Inc SQNM
Common Stock
2015-12-15 Buy 20,000 $1.41 28,200
Sequenom Inc SQNM
Common Stock
2015-12-14 Buy 20,000 $1.26 25,200
Sequenom Inc SQNM
Common Stock
2015-12-14 Buy 428,000 $1.30 556,400
Sequenom Inc SQNM
Common Stock
2015-12-10 Buy 253,565 $1.36 344,848
Sequenom Inc SQNM
Common Stock
2015-12-09 Buy 213,000 $1.32 281,160
Sequenom Inc SQNM
Common Stock
2015-12-08 Buy 325,000 $1.24 403,000
showing 20 of 32 most recent transactions
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com